Day: January 4, 2023

HOLLAND LANDING, Ontario, Jan. 04, 2023 (GLOBE NEWSWIRE) — Inscape Corporation (“Inscape” or the “Company”) (TSX: INQ), and HUK 121 Limited (the “Offeror”), jointly announce that no additional shares were deposited during the mandatory 10-day extension period under the offer dated November 17, 2022 (the “Offer”) made to shareholders of Inscape. The Offer, which initially expired on December 23, 2022 and was subsequently extended until 5:00 p.m. (Toronto time) on January 3, 2023, has now expired and will not be further extended by the Offeror. On December 23, 2022, 12,661,625 Common Shares (representing approximately 88.05% of the issued and outstanding Common Shares) (the “Deposited Shares”) were deposited to the Offer and taken up by the Offeror. The aggregate consideration payable for the Deposited Shares was approximately $88,631.38....

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) —   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the company will participate in the 41st Annual J.P. Morgan Healthcare Conference. Scott Koenig, M.D., Ph.D., President & Chief Executive Officer of MacroGenics, will provide a business update on Thursday, January 12, 2023, at 9:45 am PT / 12:45 pm ET. A webcast of the above presentation may be accessed under “Events & Presentations” in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of this webcast on its website for 30 days.    About MacroGenics, Inc.MacroGenics (the...

MONACO, Jan. 04, 2023 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”), announced today that (i) it has purchased its common shares in the open market, (ii) the President of the Company, Robert Bugbee, has purchased call options on the common shares of the Company, (iii) it has received a commitment for a new credit facility and (iv) the Company will participate in at least six investor events during the first quarter of 2023. Purchase of Common Shares Recently, the Company purchased 415,062 of its common shares in the open market at an average price of $51.35 per share as part of the Company’s securities repurchase program. Purchase of Call Options by the President of the Company The President of the Company, Robert Bugbee, has purchased call options on 400,000 common shares (or 4,000 call...

TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, will release its fourth quarter and full year 2022 results after the market closes on Thursday, February 9th, 2023. The company will host a conference call for analysts and investors on Friday, February 10th, 2023 at 9:00 a.m. ET. Conference call participants will be David Clare, President and Chief Executive Officer and David Scotland, Chief Financial Officer. To listen to the call via live audio webcast, please follow the link below:https://edge.media-server.com/mmc/p/nqjvw2ky A replay of the call will be available through the link above. About Trisura Group Trisura Group Ltd. is a specialty insurance provider operating in the surety, risk solutions, corporate insurance, fronting and...

MINNEAPOLIS, Jan. 04, 2023 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company held its adjourned special meeting of stockholders on January 4, 2023 at 2:00 p.m. (Central Time) (the “Special Meeting”). At the time of the Special Meeting, stockholders (i) approved the Warrant Proposal (as defined below) and (ii) authorized one or more adjournments of the meeting of stockholders to solicit additional proxies in the event there were insufficient votes to approve the Warrant Proposal. A total of 3,815,782 shares of the Company’s common stock were present at the Special Meeting virtually or by proxy, which represents approximately 36% of the shares of common stock outstanding as of the record date for the Special...

Carlsbad, CA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors for the purchase of 1,052,631 shares of common stock (or certain pre-funded warrants in lieu thereof) at a purchase price per common share of $2.375. Certain investors received unregistered pre-funded warrants in the private placement in lieu of common stock, subject to beneficial ownership limitations. The company has also issued to the investors, in the private placement, unregistered warrants to purchase up to 1,052,631 shares of common stock (the “Common Warrants”). These Common...

• Maximum Potential Dilution of Approximately 23.04%, Based on Share Capital of Cellectis as of September 30, 2022 NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) — Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”), pursuant to which it may offer and sell to eligible investors a maximum gross amount of up to $60.0 million of American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis, nominal value €0.05 per share, from time to time in sales deemed to be an “at the market offering” pursuant to the terms of a sales agreement with Jefferies...

SANTA ANA, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQX: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a cannabis company with operations in California, reopens its Blum San Leandro dispensary, spins off two Oregon assets, and names Sabas Carrillo as Chief Executive Officer and as a member of the board of directors, Tracy McCourt as its Chief Revenue Officer, and Jim Miller as its Chief Operating Officer. Operational Updates On December 28, 2022, the Company closed on a Management Services Agreement (the “MSA”) with Brick City Productions, Inc. (the “Operator”) to re-open and fully operate the Company’s San Leandro dispensary, including operations management, inventory management, labor administration, vendor relations, and customer service for a term of 12 months. The Operator is also providing...

Riot Achieves Numerous Key Milestones and Produces All-Time High of 659 Bitcoin in December 2022Riot’s Rockdale Facility The Company is pleased to announce that Building D has reached completion, with the final installation of indoor water cooling frames and completion of electrical testing, and miners deployed. Progress continues in Building E, where Riot’s construction and engineer teams remain focused on the installation of the air-cooling rack system, electrical installation and testing.Riot Platform’s Hash Rate Capacity Growth Graph Updated December 2022 During Q1 2023, Riot anticipates a total self-mining hash rate capacity of 12.5 EH/s, assuming full deployment of approximately 115,450 Antminer ASICs, but excluding any potential incremental productivity gains from the Company’s utilization of 200 MW of immersion-cooling...